Free Trial
→ Collect $7k per month from Tesla’s SECRET dividend (From Investors Alley) (Ad)

MeiraGTx Q3 2023 Earnings Report

MeiraGTx logo
$7.30 +0.47 (+6.88%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

MeiraGTx EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.63
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$5.10 million
Expected Revenue
$3.54 million
Beat/Miss
Beat by +$1.56 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q3 2023
Date
11/14/2023
Time
N/A

Conference Call Resources

Powered by Quartr

MeiraGTx Earnings Headlines

MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release
February 21 at 4:16 PM | marketwatch.com
MeiraGTx announces publication of data on rAAV8.hRKp.AIPL1 efficacy
February 21 at 4:16 PM | markets.businessinsider.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder
February 21 at 4:16 PM | msn.com
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
February 21 at 6:30 AM | globenewswire.com
MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions
January 30, 2025 | finance.yahoo.com
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

View MeiraGTx Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles